2004 - Karo Bio

The collaboration project with Wyeth Pharmaceuticals on atherosclerosis advanced to predevelopment status in June, yielding a milestone payment to Karo Bio. Research terms extended with one year through August 2005.

Bristol-Myers Squibb decided to return project rights, including lead compound KB2115, to Karo Bio in April.
Cost savings initiatives, including a staff reduction, was implemented to re-allocate resources to drug development activities.
Successful new share issue completed in October, generating in total MSEK 119,6 before transaction cost.